​FDA Approvals

 

 

New Treatment for Liver Cancer Gets FDA Approval1263The approval expands the use of the anticancer therapeutic regorafenib (Stivarga) to a third cancer type. It is the first new treatment option for liver cancer in a decade.5/15/2017 8:08:19 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1705017_Therapeutic_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Treatment for Liver Cancer Gets FDA ApprovalThe approval expands the use of the anticancer therapeutic regorafenib (Stivarga) to a third cancer type. It is the first new treatment option for liver cancer in a decade.40
Targeting Metastatic Lung Cancer1255The U.S. Food and Drug Administration adds a fourth molecularly targeted therapeutic option for the treatment of ALK-positive lung cancer.5/15/2017 7:26:43 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1705018_Lung_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Metastatic Lung CancerThe U.S. Food and Drug Administration adds a fourth molecularly targeted therapeutic option for the treatment of ALK-positive lung cancer.39
New PARP Inhibitor Approved for Ovarian Cancer14211The U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be used to treat women with ovarian cancer.4/26/2017 2:38:36 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1704018_Ovarian_150x190_2.jpg" style="BORDER&#58;0px solid;" />New PARP Inhibitor Approved for Ovarian CancerThe U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be used to treat women with ovarian cancer.38
New Immuotherapeutic Approved for Rare Skin Cancer14210The U.S. Food and Drug Administration decision makes avelumab the first-ever approved treatment for metastatic Merkel cell carcinoma.4/26/2017 2:01:54 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1704019_MerkelCell_150x190_1a.jpg" style="BORDER&#58;0px solid;" />New Immuotherapeutic Approved for Rare Skin CancerThe U.S. Food and Drug Administration decision makes avelumab the first-ever approved treatment for metastatic Merkel cell carcinoma.37
Immunotherapeutic Approved for Fourth Cancer Type1952The FDA has approved the immunotherapeutic pembrolizumab to treat Hodgkin lymphoma.3/30/2017 12:40:09 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/pembrolizumab_HandNCancers_Approval-150x190a.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Approved for Fourth Cancer TypeThe FDA has approved the immunotherapeutic pembrolizumab to treat Hodgkin lymphoma.36
Targeting Advanced Breast Cancer5539The FDA approved a molecularly targeted therapeutic for postmenopausal women with HR-positive, HER2-negative breast cancer.3/29/2017 6:34:22 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1703059_BreastCancer_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Advanced Breast CancerThe FDA approved a molecularly targeted therapeutic for postmenopausal women with HR-positive, HER2-negative breast cancer.35
Use of Immunotherapeutic Expanded to Bladder Cancer1954The U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for six types of cancer.2/8/2017 6:54:03 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1702007_bladder_150x190_1.jpg" style="BORDER&#58;0px solid;" />Use of Immunotherapeutic Expanded to Bladder CancerThe U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for six types of cancer.33
Molecularly Targeted Therapeutic Approved for Another Type of Non-Hodgkin Lymphoma5530The U.S. Food and Drug Administration action means ibrutinib is now an approved treatment for three types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.2/8/2017 7:01:49 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1702006_Lymphoma_150x190_1.jpg" width="177" style="BORDER&#58;0px solid;" />Molecularly Targeted Therapeutic Approved for Another Type of Non-Hodgkin LymphomaThe U.S. Food and Drug Administration action means ibrutinib is now an approved treatment for three types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.34
New Molecularly Targeted Therapeutic Approved for Ovarian Cancer5531The newly approved therapeutic is for treating women whose cancers test positive for BRCA1 and BRCA2 mutations with a new genetic test.1/25/2017 7:41:03 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1612058_Ovarian_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Molecularly Targeted Therapeutic Approved for Ovarian CancerThe newly approved therapeutic is for treating women whose cancers test positive for BRCA1 and BRCA2 mutations with a new genetic test.32
Immunotherapeutic Use Expanded to Head and Neck Cancer1960The U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for five types of cancer.11/17/2016 3:18:31 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1611023_Immunothera_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Head and Neck CancerThe U.S. Food and Drug Administration decision means nivolumab is now an approved treatment for five types of cancer.31

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300